Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

Korber Group: Somatic Evolution Research Group

Khan Lab: Engineering Human Pre-Clinical Models

We engineer complex human models to dissect how cell-to-cell and cross-tissue interactions shape health and disease. By recreating specialised microenvironments – from bone marrow to cardiac tissue – we study how ageing and disease can drive changes in these niches. Our goal is to ultimately use these approaches as translational tools to identify new therapies and validate them in relevant, human pre-clinical platforms.

Sharma Group: Mechanistic T Cell Genomics

Our research team is focused on uncovering the mechanisms that govern T cell signaling, with the goal of precisely engineering immune cells for immunotherapies.

Antanaviciute Group: Computational Biology and Tissue Immunology

Tan Group: Next-Generation Vaccines against Infectious Diseases

Rijal Group

Desborough Group: Platelet disorders and transfusion

Curry Group: Endothelial regulation of haemostasis in health and disease

We study the mechanisms by which vascular endothelial cells regulate haemostasis in health and in acquired bleeding disorders, namely trauma-induced coagulopathy, to better understand disease pathogenesis and identify novel therapeutic targets.

Zimmermann Group: Iron Nutrition - Stable Isotopes and Therapeutics

The overarching goal of our research is to improve iron nutrition and reduce the burden of anaemia among women and children. To achieve this, we employ innovative stable iron isotope techniques to precisely trace iron absorption, distribution, and utilization in the human body. These approaches inform the design and development of novel iron therapeutics. By integrating mechanistic understanding with therapeutic innovation, our work aims to deliver iron interventions with enhanced safety and efficacy.

Koohy Group: Machine Learning and Integrative Approaches in Immunology

We would like to understand the functional and molecular mechanisms of the immune system in various immunologically important conditions such as cancer, infection, autoimmune disease as well as ageing. We have a special interest in computational cancer immunotherapy such as antigen presentation, neo-antigen identification and T cell recognition of neo-antigens as well as interrogating the immune response to personalized vaccines from neo-antigens.

Simmons Group: Intestinal Immunity in Health and Disease

We define how the immune system functions in the intestine to promote health. We uncover the immune pathogenesis of intestinal diseases such as inflammatory bowel disease to develop better ways to treat these disorders.

Chakraverty Group: Haematopoietic Transplantation and Immunotherapy

Our group is interested in developing novel immunotherapeutic approaches for leukaemia. Clinical approaches currently used include allogeneic haematopoietic stem cell transplantation, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. While each of these approaches can be successful, they also fail in many patients as a result of tumour adaptations or diminished function of immune cells. Enhanced immunity can also lead to immune-related adverse events due to on- or off-target effects. We are exploring the mechanisms that underpin these failures and using this information to devise new strategies that can be translated into early phase clinical trials.

Psaila Group: Megakaryocytes, Platelets and Myeloproliferative Neoplasms

We focus on four key areas: (1) Dissecting how blood cancers create 'self-reinforcing' niches that promote clonal expansion and protect malignant clones from immunotherapies; (2) Development and application of human bone marrow organoids to study normal and malignant haematopoiesis and validate targets in a relevant tissue microenvironment; (3) Developing novel strategies to selectively target cancer stem cells and pathological megakaryocytes in myelofibrosis, a severe bone marrow malignancy; (4) Understanding our recent discovery that platelets contain a repertoire of DNA fragments sequestered from cell free DNA, and confirming clinical utility for cancer detection and for pre-natal diagnosis.

Davies Group: Genomics and Clinical Genome Editing

We are primarily interested in understanding how the genome functions and to leverage this to develop novel genome editing based cellular therapies

Patel Group: Two tier protection and metabolic genotoxicity during blood production

We study endogenous DNA damage caused by metabolites and their impact on the function of vertebrate stem cells and the ageing process

Chapman Group: Recombination mechanisms in immunity and cancer

Sims Group: Computational Genomics

We are a computational biology research group using genomic and functional genomic data to study transcriptional regulation, with projects spanning from neuroscience to musculoskeletal biology.

Townsend Group: Molecular Immunology

Jackson Group: Lymphatic Trafficking Research Group

We focus on the mechanisms controlling the migration of leucocytes and tumour cells via lymph in health and disease.

de Bruijn Group: Developmental Haematopoiesis

We study the embryonic origins of blood stem cells with the aim to inform the generation of these cells in culture, and ultimate produce clinically relevant blood stem cells for therapeutic purposes.

Load More